These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 9322804)

  • 21. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism.
    Homsanit M; Sriussadaporn S; Vannasaeng S; Peerapatdit T; Nitiyanant W; Vichayanrat A
    Clin Endocrinol (Oxf); 2001 Mar; 54(3):385-90. PubMed ID: 11298092
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A study of untreated Graves' patients with undetectable TSH binding inhibitor immunoglobulins and the effect of anti-thyroid drugs.
    Kawai K; Tamai H; Matsubayashi S; Mukuta T; Morita T; Kubo C; Kuma K
    Clin Endocrinol (Oxf); 1995 Nov; 43(5):551-6. PubMed ID: 8548939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum thyroglobulin concentration as an indicator for assessing thyroid stimulation in patients with Graves' disease during antithyroid drug therapy.
    Aizawa T; Ishihara M; Koizumi Y; Hashizume K; Takasu N; Yamada T; Kobayashi I; Watanabe T; Shimizu Z
    Am J Med; 1990 Aug; 89(2):175-80. PubMed ID: 2166430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients.
    Tamai H; Hayaki I; Kawai K; Komaki G; Matsubayashi S; Kuma K; Kumagai LF; Nagataki S
    J Clin Endocrinol Metab; 1995 May; 80(5):1481-4. PubMed ID: 7744989
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism.
    Hashizume K; Ichikawa K; Sakurai A; Suzuki S; Takeda T; Kobayashi M; Miyamoto T; Arai M; Nagasawa T
    N Engl J Med; 1991 Apr; 324(14):947-53. PubMed ID: 1900575
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A patient-specific treatment model for Graves' hyperthyroidism.
    Pandiyan B; Merrill SJ; Di Bari F; Antonelli A; Benvenga S
    Theor Biol Med Model; 2018 Jan; 15(1):1. PubMed ID: 29310665
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An elevation of serum immunoglobulin E provides a new aspect of hyperthyroid Graves' disease.
    Yamada T; Sato A; Komiya I; Nishimori T; Ito Y; Terao A; Eto S; Tanaka Y
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2775-8. PubMed ID: 10946880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of colestipol in the treatment of hyperthyroidism.
    Hagag P; Nissenbaum H; Weiss M
    J Endocrinol Invest; 1998 Dec; 21(11):725-31. PubMed ID: 9972670
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma selectin levels in patients with Graves' disease.
    Hara H; Sugita E; Sato R; Ban Y
    Endocr J; 1996 Dec; 43(6):709-13. PubMed ID: 9075611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum thyroid-stimulating antibody, thyroglobulin levels, and thyroid suppressibility measurement as predictors of the outcome of combined methimazole and triiodothyronine therapy in Graves' disease.
    Werner RS; Romaldini JH; Farah CS; Werner MC; Bromberg N
    Thyroid; 1991; 1(4):293-9. PubMed ID: 1688155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
    Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
    Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease.
    Chen JJ; Ladenson PW
    J Clin Endocrinol Metab; 1986 Jul; 63(1):102-6. PubMed ID: 2423547
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triiodothyronine-predominant Graves' disease in childhood: detection and therapeutic implications.
    Harvengt J; Boizeau P; Chevenne D; Zenaty D; Paulsen A; Simon D; Guilmin Crepon S; Alberti C; Carel JC; Léger J
    Eur J Endocrinol; 2015 Jun; 172(6):715-23. PubMed ID: 25766047
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The relationship of psychological factors to the prognosis of hyperthyroidism in antithyroid drug-treated patients with Graves' disease.
    Fukao A; Takamatsu J; Murakami Y; Sakane S; Miyauchi A; Kuma K; Hayashi S; Hanafusa T
    Clin Endocrinol (Oxf); 2003 May; 58(5):550-5. PubMed ID: 12699435
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroid function in wholly breast-feeding infants whose mothers take high doses of propylthiouracil.
    Momotani N; Yamashita R; Makino F; Noh JY; Ishikawa N; Ito K
    Clin Endocrinol (Oxf); 2000 Aug; 53(2):177-81. PubMed ID: 10931098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapy of Graves' disease with sodium ipodate is associated with a high recurrence rate of hyperthyroidism.
    Martino E; Balzano S; Bartalena L; Loviselli A; Sica V; Petrini L; Grasso L; Piga M; Braverman LE
    J Endocrinol Invest; 1991 Nov; 14(10):847-51. PubMed ID: 1687043
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.